Tempest Therapeutics/$TPST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tempest Therapeutics
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Ticker
$TPST
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
24
Website
TPST Metrics
BasicAdvanced
$30M
-
-$17.38
-2.33
-
Price and volume
Market cap
$30M
Beta
-2.33
52-week high
$11.95
52-week low
$5.43
Average daily volume
91K
Financial strength
Current ratio
1.702
Quick ratio
1.632
Long term debt to equity
70.547
Total debt to equity
117.713
Interest coverage (TTM)
-40.57%
Profitability
EBITDA (TTM)
-44.619
Management effectiveness
Return on assets (TTM)
-73.47%
Return on equity (TTM)
-282.07%
Valuation
Price to book
2.29
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
-0.546
Free cash flow yield (TTM)
-183.18%
Free cash flow per share (TTM)
-13.244
Growth
Earnings per share change (TTM)
-21.24%
3-year earnings per share growth (CAGR)
-38.56%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tempest Therapeutics stock?
Tempest Therapeutics (TPST) has a market cap of $30M as of August 01, 2025.
What is the P/E ratio for Tempest Therapeutics stock?
The price to earnings (P/E) ratio for Tempest Therapeutics (TPST) stock is 0 as of August 01, 2025.
Does Tempest Therapeutics stock pay dividends?
No, Tempest Therapeutics (TPST) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Tempest Therapeutics dividend payment date?
Tempest Therapeutics (TPST) stock does not pay dividends to its shareholders.
What is the beta indicator for Tempest Therapeutics?
Tempest Therapeutics (TPST) has a beta rating of -2.33. This means that it has an inverse relation to market volatility.